Recent articles

Drugs to be avoided II

This article is an adaptation of ‘Towards better patient care: drugs to avoid in 2018’, published in our French sister journal Prescrire International, 2018; 27 (192): 107.1-107.9.
  • In view of i ...

Read article


Cardiovascular safety of febuxostat

  • Like patients with diabetes, patients with gout represent, in absolute terms, a large group of patients at clearly increased cardiovascular risk. It is clinically relevant to know the cardiovasc ...

Read article


Recent research into rivaroxaban

  • Rivaroxaban has clearly found its way into Dutch medical practice, for a limited number of registered indications: for venous thrombo-embolism (treatment and prevention) and for the prevention o ...

Read article


Proton pump inhibitors for infants

  • Regurgitation by infants and gastro-oesophageal reflux are physiological phenomena and do not require medical treatment. Randomised studies into such medical treatment have found no evidence for ...

Read article


Cardiovascular safety of canagliflozin


Adding canagliflozin to an existing therapy in patients with type 2 diabetes and high cardiovascular risk is just as safe as adding a placebo, but may possibly offer only marginally greater cardi ...

Read article